1431470-12-0

Basic information

• Product Name: 4-bromo-pyridine-2-carboxylic acid benzyl(tetrahydropyran-2-yloxy)amide
• Synonyms: 4-bromo-pyridine-2-carboxylic acid benzyl(tetrahydropyran-2-yloxy)amide
• CAS NO: 1431470-12-0
• Molecular Weight: 391.264
• Mol File: 1431470-12-0.mol

Chemical Properties

• CAS DataBase Reference: 4-bromo-pyridine-2-carboxylic acid benzyl(tetrahydropyran-2-yloxy)amide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-pyridine-2-carboxylic acid benzyl(tetrahydropyran-2-yloxy)amide(1431470-12-0)
• EPA Substance Registry System: 4-bromo-pyridine-2-carboxylic acid benzyl(tetrahydropyran-2-yloxy)amide(1431470-12-0)

Safety Data

• Hazardous Substances Data: 1431470-12-0(Hazardous Substances Data)

Upstream product

• 30766-03-1 4-bromo-2-picolinic acid 
• 110-87-2 3,4-dihydro-2H-pyran 
• 1431470-11-9 4-bromopyridine-2-carboxylic acid benzylhydroxyamide 
• 64197-01-9 4-bromopyridine-2-carbonyl chloride 
• 29601-98-7 N-benzylhydroxylamine hydrochloride 

Downstream Products

• 1431470-14-2 4-aminopyridine-2-carboxylic acid benzyl(tetrahydropyran-2-yloxy)amide 
• 1431469-05-4 4-phenylpyridine-2-carboxylic acid benzylhydroxyamide 
• 1431608-21-7 4,4-difluoro-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-2'-carboxylic acid benzylhydroxyamide 
• 1431470-13-1 4-azido-pyridine-2-carboxylic acid benzyl-(tetrahydro-pyran-2-yloxy)amide 

Relevant articles and documents

Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease

The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease

The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.